New hope for catheter patients: expanded access to Infection-Fighting drug DefenCath
NCT ID NCT06707480
First seen May 20, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This expanded access program offers DefenCath, a catheter lock solution containing taurolidine and heparin, to adult and pediatric patients who need a catheter but cannot join ongoing clinical trials or do not meet the current FDA-approved label. The goal is to prevent central line-associated bloodstream infections (CLABSIs) in these patients. The program is available now and aims to provide broader access to this preventive treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATHETER-RELATED BLOODSTREAM INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DefenCath (taurolidine and heparin catheter lock solution)
What this could lead to
If successful, this program could help prevent serious bloodstream infections in patients who need catheters but cannot join clinical trials or use the approved treatment.
What could go wrong
This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. Results may not apply to all patients, and risks like bleeding or allergic reactions remain possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.